CHRISTINE NGUYEN: Open Payments
NPI 1609375385 · OAKLAND, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,286 in 55 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $474 · 2025 $1,286
Food & beverage: $1,286
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 11 | $275 |
| ABBVIE INC. | 10 | $231 |
| Alkermes, Inc. | 8 | $194 |
| Neurocrine BioSciences, Inc. | 7 | $170 |
| Axsome Therapeutics, Inc. | 4 | $107 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $86 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Bausch Health US, LLC | 2 | $42 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $33 |
| Almatica Pharma LLC | 1 | $30 |
Products named: COBENFY, VRAYLAR, INGREZZA, ARISTADA, Auvelity, TRINTELLIX, REXULTI, APLENZIN.
Industry payments across CA — which companies pay providers there.
